Blueprint Medicines Co. (NASDAQ:BPMC) Receives $126.56 Average Target Price from Analysts
Blueprint Medicines Co. (NASDAQ:BPMC – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the eighteen analysts that are currently covering the firm, Marketbeat.com reports. Four analysts have rated the stock with a hold recommendation, thirteen have assigned a buy recommendation and one has given a strong buy recommendation to the company. […]
Blueprint Medicines Co. (NASDAQ:BPMC – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the eighteen analysts that are currently covering the firm, Marketbeat.com reports. Four analysts have rated the stock with a hold recommendation, thirteen have assigned a buy recommendation and one has given a strong buy recommendation to the company. […]
